Tirzepatide is administered through a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm
Both drugs contain the same active ingredient and are classified as glucagon-like peptide-1 (GLP-1) receptor agonists
*Correspondence: Beatriz Rodrguez Jimnez, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
According to one study, regular semaglutide use can produce an average of approximately 10.9 percent total body weight loss in six months
it's showing up in conversations about body composition, energy, recovery, and longevity
Tone Unification and Maintenance Phase Sustained brightening and pigmentation control